Home > Investor Relations > Financial Results > Revenue by Product

Revenue by Product

(Billions of Yen)
  2014 2015 2016
Sales 436.9 468.4 472.7
  Excl.Tamiflu® 423.8 460.2 459.2
  Domestic 349.5 378.0 379.7
  Oncology 188.9 215.7 220.3
  Avastin® 82.3 93.8 92.1
Herceptin® 31.2 32.7 34.1
Rituxan® 26.2 29.0 32.1
Xeloda® 10.4 11.1 12.3
Tarceva® 11.5 11.6 11.5
Perjeta® 9.1 10.6 11.9
Alecensa®* 1.4 8.0 11.9
Kadcyla®* 4.0 7.3 8.3
Neutrogin® 5.9 4.9 4.1
Zelboraf®* - 0.5 0.4
Other products 6.9 6.1 1.7
Bone and joint diseases 69.6 79.4 86.1
  Actemra® 24.1 26.8 30.2
Edirol® 19.2 23.1 26.7
Suvenyl® 10.7 10.5 9.3
Bonviva® 3.4 5.4 7.3
Alfarol® 4.9 4.2 3.2
Other products 7.4 9.5 9.4
Renal diseases 44.7 45.4 41.1
  Mircera® 22.6 23.8 24.2
Oxarol® 12.2 12.9 9.1
Epogin® 6.6 5.9 5.2
Other products 3.4 2.8 2.6
Transplant, Immunology, and Infectious diseases 20.8 15.9 13.7
  CellCept® 6.5 7.0 7.9
Copegus® 3.1 2.9 1.6
Pegasys® 7.0 1.9 0.5
Other products 4.2 4.0 3.6
Others 25.6 21.7 18.5
  Sigmart® 6.4 5.2 3.8
Other products 19.2 16.6 14.7
Overseas 74.3 82.2 79.5
    Actemra® 55.7 63.6 60.3
To Roche 55.1 62.6 59.1
Neutrogin® 15.7 14.8 12.2
Alecensa®** - 0.5 3.7
Akynzeo®** - 0.0 0.1
Aloxi®** - 0.3 0.2
Other products 2.9 3.0 3.0
Tamiflu® 13.0 8.2 13.5
  Ordinary use 12.9 8.2 12.0
Govt. stockpiles etc. 0.2 0.0 1.5
Royalties and other operating income 24.2 30.4 19.1
Revenues (total) 461.1 498.8 491.8
    Domestic 372.9 390.0 395.1
Overseas 88.2 108.8 96.6

*Kadcyla (launched in April 2014), Alecensa (launched in September 2014), Zelboraf (launched in February 2015)
**Aloxi (launched in January 2015 (UK)), Alecensa (launched in December 2015 (US)), Akynzeo (launched in September 2015 (UK), December 2015 (Ireland))

Sales by Strategic Field (FY2016)

Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.
Domestic sales are shown by each disease area.